XDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

Although both blepharitis and styes affect the eyelids, the two conditions have different symptoms, causes, and treatment options. To help prevent developing a stye or blepharitis, a person can ...

Blepharitis can affect anyone, including people who do not have eczema. Eczema is characterized by flare-ups, which last for weeks or months, and remissions. Your healthcare provider will design a ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...

“For years, millions of patients with Demodex blepharitis have struggled with limited, suboptimal treatment options and the frustration of not being able to address the root cause of their ...

“For years, millions of patients with Demodex blepharitis have struggled with limited, suboptimal treatment options and the frustration of not being able to address the root cause of their ...

To improve dry eye problems with contact lenses, your healthcare provider may recommend: Blepharitis is an inflammation of the eyelids. While it can affect people of any age, blepharitis tends to ...